Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ)

Keisuke Horiuchi, Hideo Morioka, Kazumasa Nishimoto, Yoshihisa Suzuki, Michiro Susa, Robert Nakayama, Akira Kawai, Hiroshi Sonobe, Hironari Takaishi, Toshihumi Ozaki, Hiroo Yabe, Kazuo Umezawa, Yoshiaki Toyama

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Synovial sarcoma is a relatively common soft tissue sarcoma with an aggressive clinical course. Although surgery is currently the first treatment modality, improvement of adjuvant chemotherapy is deemed essential to improve the clinical outcome. Nuclear factor-κB (NF-κB) is constitutively activated in various cancer cells and has emerged as a potential therapeutic molecular target; however, the possible involvement of NF-κB in the pathology of sarcomas remains to be clarified. Herein we examined the effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) on two synovial sarcoma-derived cell lines, HS-SY-II and SYO-1. The growth of both cell lines was completely inhibited by DHMEQ and apoptosis was induced at 10 μg/ml. Additionally, we found that DHMEQ showed additive effects when used in combination with other cytotoxic agents. These observations indicate that inhibition of NF-κB activity may serve as a potential therapeutic target for synovial sarcoma.

Original languageEnglish
Pages (from-to)336-344
Number of pages9
JournalCancer Letters
Volume272
Issue number2
DOIs
Publication statusPublished - Dec 18 2008

Fingerprint

Synovial Sarcoma
Apoptosis
Cell Line
Sarcoma
Growth
Cytotoxins
Adjuvant Chemotherapy
Therapeutics
Pathology
dehydroxymethylepoxyquinomicin
Neoplasms

Keywords

  • Chemotherapy
  • Dehydroxymethylepoxyquinomicin (DHMEQ)
  • NF-κB inhibitor
  • Synovial sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). / Horiuchi, Keisuke; Morioka, Hideo; Nishimoto, Kazumasa; Suzuki, Yoshihisa; Susa, Michiro; Nakayama, Robert; Kawai, Akira; Sonobe, Hiroshi; Takaishi, Hironari; Ozaki, Toshihumi; Yabe, Hiroo; Umezawa, Kazuo; Toyama, Yoshiaki.

In: Cancer Letters, Vol. 272, No. 2, 18.12.2008, p. 336-344.

Research output: Contribution to journalArticle

Horiuchi, K, Morioka, H, Nishimoto, K, Suzuki, Y, Susa, M, Nakayama, R, Kawai, A, Sonobe, H, Takaishi, H, Ozaki, T, Yabe, H, Umezawa, K & Toyama, Y 2008, 'Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ)', Cancer Letters, vol. 272, no. 2, pp. 336-344. https://doi.org/10.1016/j.canlet.2008.07.021
Horiuchi, Keisuke ; Morioka, Hideo ; Nishimoto, Kazumasa ; Suzuki, Yoshihisa ; Susa, Michiro ; Nakayama, Robert ; Kawai, Akira ; Sonobe, Hiroshi ; Takaishi, Hironari ; Ozaki, Toshihumi ; Yabe, Hiroo ; Umezawa, Kazuo ; Toyama, Yoshiaki. / Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ). In: Cancer Letters. 2008 ; Vol. 272, No. 2. pp. 336-344.
@article{e2deaa212206463e9814f5aa67be5917,
title = "Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ)",
abstract = "Synovial sarcoma is a relatively common soft tissue sarcoma with an aggressive clinical course. Although surgery is currently the first treatment modality, improvement of adjuvant chemotherapy is deemed essential to improve the clinical outcome. Nuclear factor-κB (NF-κB) is constitutively activated in various cancer cells and has emerged as a potential therapeutic molecular target; however, the possible involvement of NF-κB in the pathology of sarcomas remains to be clarified. Herein we examined the effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) on two synovial sarcoma-derived cell lines, HS-SY-II and SYO-1. The growth of both cell lines was completely inhibited by DHMEQ and apoptosis was induced at 10 μg/ml. Additionally, we found that DHMEQ showed additive effects when used in combination with other cytotoxic agents. These observations indicate that inhibition of NF-κB activity may serve as a potential therapeutic target for synovial sarcoma.",
keywords = "Chemotherapy, Dehydroxymethylepoxyquinomicin (DHMEQ), NF-κB inhibitor, Synovial sarcoma",
author = "Keisuke Horiuchi and Hideo Morioka and Kazumasa Nishimoto and Yoshihisa Suzuki and Michiro Susa and Robert Nakayama and Akira Kawai and Hiroshi Sonobe and Hironari Takaishi and Toshihumi Ozaki and Hiroo Yabe and Kazuo Umezawa and Yoshiaki Toyama",
year = "2008",
month = "12",
day = "18",
doi = "10.1016/j.canlet.2008.07.021",
language = "English",
volume = "272",
pages = "336--344",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ)

AU - Horiuchi, Keisuke

AU - Morioka, Hideo

AU - Nishimoto, Kazumasa

AU - Suzuki, Yoshihisa

AU - Susa, Michiro

AU - Nakayama, Robert

AU - Kawai, Akira

AU - Sonobe, Hiroshi

AU - Takaishi, Hironari

AU - Ozaki, Toshihumi

AU - Yabe, Hiroo

AU - Umezawa, Kazuo

AU - Toyama, Yoshiaki

PY - 2008/12/18

Y1 - 2008/12/18

N2 - Synovial sarcoma is a relatively common soft tissue sarcoma with an aggressive clinical course. Although surgery is currently the first treatment modality, improvement of adjuvant chemotherapy is deemed essential to improve the clinical outcome. Nuclear factor-κB (NF-κB) is constitutively activated in various cancer cells and has emerged as a potential therapeutic molecular target; however, the possible involvement of NF-κB in the pathology of sarcomas remains to be clarified. Herein we examined the effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) on two synovial sarcoma-derived cell lines, HS-SY-II and SYO-1. The growth of both cell lines was completely inhibited by DHMEQ and apoptosis was induced at 10 μg/ml. Additionally, we found that DHMEQ showed additive effects when used in combination with other cytotoxic agents. These observations indicate that inhibition of NF-κB activity may serve as a potential therapeutic target for synovial sarcoma.

AB - Synovial sarcoma is a relatively common soft tissue sarcoma with an aggressive clinical course. Although surgery is currently the first treatment modality, improvement of adjuvant chemotherapy is deemed essential to improve the clinical outcome. Nuclear factor-κB (NF-κB) is constitutively activated in various cancer cells and has emerged as a potential therapeutic molecular target; however, the possible involvement of NF-κB in the pathology of sarcomas remains to be clarified. Herein we examined the effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) on two synovial sarcoma-derived cell lines, HS-SY-II and SYO-1. The growth of both cell lines was completely inhibited by DHMEQ and apoptosis was induced at 10 μg/ml. Additionally, we found that DHMEQ showed additive effects when used in combination with other cytotoxic agents. These observations indicate that inhibition of NF-κB activity may serve as a potential therapeutic target for synovial sarcoma.

KW - Chemotherapy

KW - Dehydroxymethylepoxyquinomicin (DHMEQ)

KW - NF-κB inhibitor

KW - Synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=55949136835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55949136835&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2008.07.021

DO - 10.1016/j.canlet.2008.07.021

M3 - Article

VL - 272

SP - 336

EP - 344

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -